Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group

Breast Cancer Research and Treatment

Volumn 92, Issue 1, 2005, Pages 1-9

  Fountzilas, George ^a   Pectasides, Dimitrios ^b   Kalogera Fountzila, Anna ^a   Skarlos, Dimosthenis ^c   Kalofonos, Haralambos P ^d   Papadimitriou, Christos ^e   Bafaloukos, Dimitrios ^f   Lambropoulos, Stefanos ^g   Papadopoulos, Savvas ^g   Kourea, Helen ^d   Markopoulos, Christos ^e   Linardou, Helen ^h   Mavroudis, Dimitrios ^h   Briasoulis, Evangelos ⁱ   Pavlidis, Nicholaos ⁱ   Razis, Evangelia ^g   Kosmidis, Paraskevas ^g   Gogas, Helen ^e  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c Errikos Dunant Hospital   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f METROPOLITAN HOSPITAL   (Greece)

^g HYGEIA HOSPITAL   (Greece)

^h UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

ⁱ UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Advanced breast cancer; Carboplatin; Gefitinib; IRESSA; Paclitaxel

Indexed keywords

CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PACLITAXEL;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; INFORMED CONSENT; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TUMOR BIOPSY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; QUINAZOLINES; TREATMENT OUTCOME;

EID: 21044438337     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-0322-y     Document Type: Article

References (38)

1. J O'Shaughnessy D Miles S Vukelja V Moiseyenko JP Ayoub G Cervantes P Fumoleau S Jones WY Lui L Mauriac C Twelves G Van Hazel S Verma R Leonard 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823
2. G Fountzilas A Athanassiades A Kalogera-Fountzila G Aravantinos D Bafaloukos E Briasoulis N Dombros I Ioannidis N Pavlidis P Kosmidis D Skarlos 1997 Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group Eur J Cancer 33 1893 1895
3. G Fountzilas AM Dimopoulos C Papadimitriou A Kalogera-Fountzila G Aravantinos D Bafaloukos A Athanassiades C Nicolaides A Kerampoulos N Pavlidis P Kosmidis D Skarlos 1998 First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report) a phase II study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 9 1031 1034
4. Fountzilas G, Kalofonos HP, Dafni U,, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin, as first line chemotherapy in patients with advanced breast cancer, a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol in press
5. KC Chan WF Knox JM Gee J Morris RI Nicholson CS Potten NJ Bundred 2002 Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast Cancer Res 62 122 128
6. KC Chan WF Knox A Gandhi DJ Slamon CS Potten NJ Bundred 2001 Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation Br J Surg 88 412 418
7. F Ciardiello R Caputo R Bianco V Damiano G Fontanini S Cuccato S De Placido AR Bianco G Tortora 2001 Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor Clin Cancer Res 7 1459 1465
8. FM Sirotnak MF Zakowski VA Miller HI Scher MG Kris 2000 Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin Cancer Res 6 4885 4982
9. F Ciardiello R Caputo R Bianco V Damiano G Pomatico S De Placido AR Bianco G Tortora 2000 Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin Cancer Res 6 2053 2063
10. CJ Witton JR Reeves JJ Going TG Cooke JM Bartlett 2003 Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer J Pathol 200 290 297
11. J Anido P Matar J Albanell M Guzman F Rojo J Arribas S Averbuch J Baselga 2003 ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells Clin Cancer Res 9 1274 1283
12. A Alkarain J Slingerland 2004 Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer Breast Cancer Res 6 13 21
13. RB Clarke 2003 p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis Breast Cancer Res 5 162 163
14. CL Arteaga 2004 Cdk inhibitor p27Kip1 and hormone dependence in breast cancer Clin Cancer Res 10 Pt 2 368S 371S
15. LA Hammond 2003 Pharmacokinetic evaluation of gefitinib when administered with chemotherapy Clin Lung Cancer 5 suppl 1 S18 S21
16. VA Miller DH Johnson LM Krug B Pizzo L Tyson W Perez P Krozely A Sandler D Carbone RT Heelan MG Kris R Smith J Ochs 2003 Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer J Clin Oncol 21 2094 2100
17. RW Jelliffe 1973 Creatinine clearance: bedside estimate Ann Intern Med 79 604 605 (letter)
18. AH Calvert DR Newell LA Gumbrell S O'Reilly M Burnell FE Boxall ZH Siddik IR Judson ME Gore E Wiltshaw 1989 Carboplatine dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1748 1756
19. G Fountzilas A Athanassiades V Papadimitriou MA Dimopoulous D Bafaloukos G Aravantinos C Nicolaides H Kalafonos P Papakostas N Xiros E Razi 1998 Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer Oncology (Huntingt) 12 suppl 1 45 48
20. EA Perez DW Hillman PJ Stella JE Krook LC Hartmann TR Fitch AK Hatfield JA Mailliard S Nair CG Kardinal JN Ingle 2000 A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma Cancer 88 124 131
21. LR Bailey M Kris M Wolf A Kay S Averbuch J Askao M Janas K Schmidt M Fukuoka 2003 Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2 Proc Am Assoc Cancer Res 44 2nd ed 1362 (abstract LB-170)
22. P Bonomi 2003 Erlotinib: a new therapeutic approach for non-small cell lung cancer Expert Opin Investig Drugs 12 844]?» 1395 1401
23. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127 137
24. N Ravindranath D Wion P Brachet D Djakiew 2001 Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate J Androl 22 432 443
25. JG Paez PA Jänne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon K Naoki H Sasaki Y Fujii MJ Eck WJ Sellers BE Johnson M Meyerson 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500
26. TJ Lynch DW Bell R Sordella S Gurubhagavantula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska DN Louis DC Christiani J Settleman DA Haber 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2191 2193
27. F Cappuzzo E Magrini S Bartolini G Ceresoli V Ludovini V Gregorc C Ligorio L Lombardo L Crinò 2004 Improved efficacy of gefitinib therapy in phospho-Akt positive patients with advanced non-small cell lung cancer Proc Am Soc Clin Oncol 23 196 (abstract 3004)
28. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
29. Z Suo B Risberg MG Kalsson K Willman A Tierens E Skovlund JM Nesland 2002 EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 have different effects on survival J Pathol 196 17 25
30. J Kurebayashi S Okubo Y Yamamoto H Sonoo 2004 Inhibition of HER1 signaling pathway enhances antitumor affect of endocrine therapy in breast cancer Breast Cancer 11 1 38 41
31. RS Herbst G Giaccone JH Schiller RB Natale V Miller C Manegold G Scagliotti R Rosell I Oliff JA Reeves MK Wolf AD Krebs SD Averbuch JS Ochs J Grous A Fandi DH Johnson 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT2 J Clin Oncol 22 785 794
32. C Pico M Martin C Jara A Barnadas A Pelegri A Balil C Camps A Frau A Rodriguez-Lescure JM Lopez-Vega J DeLa Haba A Tres I Alvarez E Alba A Arcusa A Oltra N Batista T Checa R, Perez-Carrion GEICAM Group 2004 Epirubicin- cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study Ann Oncol 15 79 87
33. G Giaccone RS Herbst C Manegold G Scagliotti R Rosell V Miller RB Natale JH Schiller J von Pawel A Pluzanska U Gatzemeier J Grous JS Ochs SD Averbuch MK Wolf P Rennie A Fandi DH Johnson 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 777 784
34. JD Hainsworth JR Gray LH Morrissey LA Kalman JK Hon A Greco 2002 Long-term follow up of patients treated with paclitaxel/carboplatin based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network J Clin Oncol 20 2937 2942
35. AH Limper 2004 Chemotherapy-induced lung disease Clin Chest Med 25 53 64
36. JJ Erasmus HP McAdams SE Rossi 2002 Drug-induced lung injury Semin Roentgenol 37 72 81
37. P Wong AN Leung GJ Berry KA Atkins JG Montoya SJ Ruoss FE Stockdale 2001 Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings AJR Am J Roentgenol 176 718 720
38. A Inoue Y Saijo M Maemondo K Gomi Y Tokue Y Kimura M Ebina T Kikuchi T Moriya T Nukiwa 2003 Severe acute interstitial pneumonia and gefitinib Lancet 361 137 139